

1 **Development of an effective immune response in adults with Down Syndrome**  
2 **after SARS-CoV-2 vaccination**

3

4 Laura Esparcia-Pinedo<sup>1(\*)</sup>, Ayla Yarci-Carrión<sup>2(\*)</sup>, Gloria Mateo-Jiménez<sup>3</sup>, Noelia  
5 Ropero<sup>1</sup>, Laura Gómez-Cabañas<sup>4</sup>, Ángel Lancho-Sánchez<sup>4</sup>, Enrique Martín-Gayo<sup>1,5</sup>,  
6 Francisco Sanchez-Madrid<sup>1,5</sup>, Fernando Moldenhauer<sup>6</sup>, Ainhoa Gutiérrez-Cobos<sup>2(#)</sup>,  
7 Diego Real de Asúa<sup>5,6(#)</sup>, Arantzazu Alfranca<sup>1,5(#,&)</sup>.

8

91. Immunology Department, Hospital Universitario de La Princesa, Instituto de  
10 Investigación Sanitaria Princesa, Madrid, Spain  
112. Microbiology Department, Hospital Universitario de La Princesa, Instituto de  
12 Investigación Sanitaria Princesa, Madrid, Spain  
133. Fundación de Investigación Biomédica del Hospital Universitario de La Princesa,  
14 Instituto de Investigación Sanitaria Princesa, Madrid, Spain  
154. Biobanco, Fundación de Investigación del Hospital Universitario de La Princesa,  
16 Instituto de Investigación Sanitaria Princesa, Madrid, Spain  
175. Department of Medicine, School of Medicine, Universidad Autónoma de Madrid,  
18 Madrid, Spain  
196. Internal Medicine Department, Hospital Universitario de La Princesa, Instituto de  
20 Investigación Sanitaria Princesa, Madrid, Spain

21

22 (\*) These authors share first authorship

23 (#) These authors share senior authorship

24 (&) **Corresponding author:**

25 Arantzazu Alfranca  
26 Immunology Department  
27 Hospital Universitario de La Princesa  
28 Dpto de León 62  
29 28006Madrid, Spain  
30 Email: [mariaaranzazu.alfranca@salud.madrid.org](mailto:mariaaranzazu.alfranca@salud.madrid.org)  
31 T: +34 915202200

32

33

34 **SUMMARY**

35 The work shows the cellular and humoral responses to SARS-CoV-2 vaccination of  
36 individuals with Down syndrome (DS) after one to three (V1) and six (V2) months. An  
37 effective immune response after six months was observed in 98% of DS individuals.

38

39 **ABSTRACT**

40

41 Immune dysregulation in individuals with Down syndrome (DS) leads to an increased  
42 risk for hospitalization and death due to COVID-19 and may impair the generation of  
43 protective immunity after vaccine administration. The cellular and humoral responses of  
44 55 DS patients who received a complete SARS-CoV-2 vaccination regime at one to three  
45 (V1) and six (V2) months were characterised. SARS-CoV-2-reactive CD4+ and CD8+ T  
46 lymphocytes with a predominant Th1 phenotype were observed at V1, and increased at  
47 V2. Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells  
48 was observed one to three months after vaccine administration. Specific IgG antibodies  
49 against SARS-CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2,  
50 respectively, though IgG titers decreased significantly between both timepoints.

51

## 52 INTRODUCTION

53 The new coronavirus disease (COVID-19) due to SARS-CoV-2 is a global health  
54 emergency since March 2020. Although COVID-19 entails no or mild symptoms in most  
55 individuals, several at-risk patient subgroups develop a severe form of the disease,  
56 leading to acute respiratory distress syndrome (ARDS) (Brodin, 2021; Ruan et al., 2020).  
57 Individuals with Down syndrome (DS), the most frequent chromosomal abnormality  
58 worldwide, are particularly vulnerable to the disease, with a 4-fold increased risk for  
59 COVID-19-related hospitalization and a 3 to 10-fold increased risk for COVID-19-related  
60 mortality (Cliff et al., 2021; Hüls et al., 2021; Wadman, 2020).

61  
62 Although this increase can be partially attributed to a higher prevalence of comorbidities  
63 associated with a poorer COVID-19-related prognosis, such as obesity, congenital heart  
64 disease (CHD) or respiratory diseases (Perera et al., 2020; Real de Asua et al., 2021)  
65 the susceptibility of this population to SARS-CoV-2 can be further explained by the  
66 immune dysregulation observed in DS. These individuals display immune features which  
67 promote the development of autoinflammatory and autoimmune conditions, and lead to  
68 an increase in the incidence of infections (Huggard et al., 2020). DS patients show higher  
69 levels of IFN-stimulated genes, which explain their higher basal levels of IFN- $\alpha$  signaling  
70 and hypersensitivity to IFN stimulation (Chung et al., 2021). Indeed, four subunits of IFN  
71 receptors are encoded on HSA21 (IFNAR1, IFNAR2, IFNGR2, and IL10RB), and an  
72 increase in IFNAR1 and IFNAR2 expression in different cell types from DS donors has  
73 been described (Kong et al., 2020). Cells from DS patients also present variable degrees  
74 of increased IFN-I proximal signaling, such as higher levels of pSTAT1 (Malle and  
75 Bogunovic, 2021). Furthermore, the increased expression of TMPRSS2, which primes  
76 the viral S protein for entry into host cells and is also encoded in HSA21, may facilitate  
77 the infection of target cells by SARS-CoV-2, while NLRP3 downregulation and increased  
78 IL-10 production could be involved in the higher risk of bacterial infectious complications  
79 in these patients (De Toma and Dierssen, 2021; Espinosa, 2020). DS individuals also  
80 have high basal levels of proinflammatory cytokines like IL-2, IL-6, or TNF- $\alpha$ , which may  
81 enhance the “cytokine storm” that underlies ARDS in this condition (Espinosa, 2020).  
82 Although the overall effect of these alterations seems deleterious and provides some  
83 proof for the worse outcomes following SARS-CoV-2 infection, the net balance between  
84 all these interplaying factors is far from clear. Indeed, a decrease in IFNAR2 has been  
85 associated with worse COVID-19 outcome (Pairo-Castineira et al., 2021), hence this  
86 mechanism would theoretically contribute to a better evolution of COVID-19 infections in  
87 DS patients.

88  
89 This immune dysregulation may impair the generation of protective immunity after  
90 vaccine administration in individuals with DS. In fact, though people with DS usually  
91 develop protective antibody responses after vaccination, overall antibody levels tend to  
92 be lower and decline faster than in individuals without DS (Joshi et al., 2011). Due to  
93 their excess mortality risk and these concerns over vaccine protection, most countries  
94 have included adults with DS, especially those over 40 years, in prioritized vaccination  
95 groups (Hüls et al., 2020). However, data on the immune response elicited by SARS-  
96 CoV-2 vaccines in the DS population are lacking, and the degree of protection achieved  
97 is unknown. A thorough characterization of the humoral and cellular immunity  
98 mechanisms underlying the response of individuals with DS to COVID-19 vaccines is  
99 needed to appropriately tailor future vaccination campaigns for this vulnerable  
100 population. Moreover, this knowledge may also shed light onto general immune  
101 mechanisms involved in the response to SARS-CoV-2, and in the development of post-  
102 vaccination responses.

103  
104 We performed a characterization of cellular and humoral responses developed in DS  
105 patients at one to three (V1) and six (V2) months after two-dose SARS-CoV-2

106 vaccination. We provide evidence of the presence of SARS-CoV-2-reactive CD4+ and  
107 CD8+ T lymphocytes with a predominant Th1 phenotype in V1, which increased in V2.  
108 Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells was  
109 observed in these patients one to three months after vaccine administration. Specific IgG  
110 antibodies against SARS-CoV-2 S protein were detected in V1, which significantly  
111 decreased in V2.

112

## 113 **RESULTS AND DISCUSSION**

114

### 115 **T cell response to SARS-CoV vaccination in DS donors**

116 To assess immune response elicited by SARS-CoV-2 vaccine in DS, we recruited 55  
117 donors whose demographic and clinical characteristics are shown in Table 1. These  
118 donors were inoculated with two doses of a SARS-CoV-2 vaccine following the  
119 recommended schedule (vaccine types, described in Table 1), and both T cell and  
120 antibody responses were analyzed before vaccine administration (V0), one to three  
121 months (V1) and six months (V2) after second vaccination. Fifty-one subjects (51/55,  
122 93%) were enrolled after having received at least one vaccination dose. To avoid any  
123 delay in official vaccination strategies, we admitted the use in these cases of biobank-  
124 stored samples (from earlier than February 2020) as baseline (V0). Median time  
125 (interquartile range) from the last dose of the recommended vaccination schedule to the  
126 first blood extraction (V1) was 62 (42-70) days, and 159 (150-172) days to the second  
127 blood extraction (V2).

128 We determined the presence of SARS-CoV-2-specific T cells in V0, V1 and V2. To  
129 assess the percentage of responsive T cells, we used an activation-induced marker  
130 (AIM) assay based on the detection of CD4+ OX40/CD137 double positive and CD8+  
131 CD69/CD137 double positive cells, after 24h in the presence of peptide pools from  
132 SARS-CoV-2 (NCAP, S1, S2, RBD domain, VME1 and Mpro proteins for V0 and S1, S2,  
133 and RBD domain for V1 and V2). In all cases, we included a human actin-derived peptide  
134 pool as a negative control, and Staphylococcal enterotoxin B (SEB) as a positive control.

135 As shown in Fig.1, we found a predominant CD4+ response (73.21% patients with  
136 specific CD4+ vs.16.36% patients with specific CD8+ in V2), which is in line with previous  
137 data in non-DS individuals (Grifoni et al., 2020). Of note, CD4+ activation against S1 and  
138 S2 was observed in a single pre-pandemic sample from V0 (Fig. 1A). We did not detect  
139 SARS-CoV-2-specific CD8+ lymphocytes in this baseline visit (Fig. 1B). SARS-CoV-2 S-  
140 responsive CD4+ cells have also been previously detected in healthy non-DS donors,  
141 and their presence is explained by a possible cross-reaction with common cold  
142 coronaviruses or other pathogens which contain SARS-CoV-2 homologous sequences  
143 (Woldemeskel et al., 2020). Interestingly, unlike our DS donors, NCAP-specific CD4+T  
144 cells have been frequently identified in healthy non-DS donors (Mateus et al., 2020), a  
145 finding which has been attributed by some authors to former exposure to SARS-CoV-2,  
146 since no NCAP-responsive CD4+ cells have been observed in pre-pandemic samples  
147 (Sekine et al., 2020). Because most V0 samples in our study were collected before the  
148 beginning of the pandemic, previous asymptomatic contact with SARS-CoV-2 can be  
149 reliably ruled out. In addition, it is conceivable that T cells recognizing NCAP might  
150 display reduced functional avidity, which would impair their detection in our activation-  
151 dependent assay. This possibility could be further supported by a feasible defect in *in*  
152 *vitro* T cell activation in DS patients, however lymphocytes from these individuals have  
153 been shown to respond *in vitro* to SEB, CMV and VZV to a similar extent as non-DS  
154 donors (Schoch et al., 2017).

155 After vaccination, the percentage of individuals with SARS-CoV-2-responsive T  
156 lymphocytes raised from 23.8% in V1 to 73.21% in V2 for CD4+, and from 8.93% in V1  
157 to 16.36% in V2 for CD8+. We could detect vaccine-elicited specific CD4+ and CD8+

158 directed against S1, S2 and RBD, with a similar pattern in V1 and V2 (Fig. 1A, B). T cell  
159 responses seem to be delayed in comparison to non-DS donors, which usually reach a  
160 higher percentage of individuals with specific T cell immunity within 4-7 weeks post  
161 SARS-CoV-2 vaccine administration (Esparcia-Pinedo L et al., 2022).

162 SARS-CoV-2 mRNA vaccines are known to promote a Th1 reaction in the general  
163 population (Sadarangani et al., 2021). Because individuals with DS usually present a  
164 higher Th1/Th2 ratio than euploid donors, a finding related to an increase in baseline  
165 IFN $\gamma$  levels in this population (Franciotta et al., 2006), we sought to determine whether  
166 vaccination also resulted in Th1 predominant response in these patients. We evaluated  
167 T helper populations in SARS-CoV-2-specific CD4+ lymphocytes and found comparable  
168 percentages of Th1 and Th2 in V1. However, a significant increase in Th1 but not Th2  
169 could be observed in V2 ( $p < 0.01$ ). As a specificity control, we determined Th1 and Th2  
170 distribution in SEB-stimulated CD4+ cells, and found no significant differences between  
171 both subsets in either V1 and V2 (Fig. 2A). A similar pattern was detected regardless of  
172 the peptide pool (S1 or S2) analyzed (Fig. 2B). In addition, we did not find gender  
173 differences in Th1 and Th2 behavior, except for a significantly higher Th2 response in  
174 V1 in male DS donors (Suppl. Fig. 2A). Of note, although Th1 increase in V2 could be  
175 observed in all DS individuals, it was higher in patients  $\leq 40$  years of age (Suppl. Fig.  
176 2B).

177 T follicular helper cells (Tfh) constitute a specialized subset of CD4+ T cells that  
178 collaborates in the activation and proliferation of B cells and the generation of high-affinity  
179 antibodies. In DS, normal counts of Tfh with a reduced B helper capacity have been  
180 reported. However other authors show increased percentages of IFN $\gamma$ -secreting Tfh  
181 (Tfh1), which are thought to promote autoimmune responses in these patients (Ottaviano  
182 et al., 2020). In vaccinated DS donors, we found a SARS-CoV-2-specific cTfh population  
183 with sustained levels between V1 and V2 (Fig. 3A). PD-1hi cTfh are thought to represent  
184 a subset of recently activated cTfh cells (Dan et al., 2021). Accordingly, we detected  
185 SARS-CoV-2-specific CD4+CXCR5+PD-1hi cells in V1 in DS donors, whose levels were  
186 slightly reduced in V2 (Fig. 3A).

187 A population of CD8+CXCR5+ cells has been described which includes several  
188 functional subsets. Among them, a CD8+CXCR5+PD-1hi subset with Tfh-like properties  
189 displays cytotoxic characteristics in germinal centers, and may support antibody  
190 production in chronic infections and autoimmune conditions (Valentine and Hoyer, 2019).  
191 This population has been recently reported to increase in acute immunization settings  
192 and collaborate in specific antibody response (Tyllis et al., 2021). We therefore  
193 investigated the presence of SARS-CoV-2 specific CD8+CXCR5+PD-1hi cells in  
194 vaccinated DS patients and found that these cells were already detectable in V1, and  
195 their levels significantly increased in V2 ( $p < 0.01$ ) (Fig. 3B), suggesting that this cell  
196 subset could also cooperate in antibody generation in DS individuals after vaccine  
197 administration, although the actual functional significance of this population remains to  
198 be determined. In sum, our results indicate that SARS-CoV-2 vaccination efficiently  
199 induces the differentiation of specific populations that collaborate in an effective antibody  
200 response.

201

## 202 **Humoral response to SARS-CoV-2 vaccination in DS individuals**

203 DS patients exhibit alterations in B lymphocyte maturation and function that may account  
204 for an impaired humoral response to vaccination. Transitional and mature naïve B cells  
205 are usually reduced by 50%, while numbers of switched memory B cells reach 10% of  
206 those found in non-DS counterparts (Carsetti et al., 2015). Similarly, a reduced frequency  
207 of switched memory B cells specific to vaccine antigens has been described in DS  
208 (Valentini et al., 2015). However, the degree of humoral response in DS individuals is  
209 highly variable among different vaccines. In this regard, influenza A/H1N1,

210 pneumococcal capsular polysaccharide, or hepatitis B virus vaccination only induce a  
211 partial antibody response (Costa-Carvalho et al., 2006; Eijvoogel et al., 2017), while  
212 conjugated pneumococcal or Hepatitis A virus vaccines have been reported to elicit  
213 adequate antibody titers. In our study, no patients were positive for anti-SARS-CoV-2  
214 IgG before vaccination. We did find detectable titers of SARS-CoV-2 S protein specific  
215 IgG in 96.4% of patients (53/55) at V1. Two patients did not develop anti-S IgG antibodies  
216 at V1, one of which showed detectable titers of IgG at V2. The percentage of positive  
217 donors was similar at V2, when detectable titers of S protein-specific IgG were observed  
218 in 98.1% of patients (52/53, two patients with no data on humoral response at this  
219 timepoint; Fig.4A and Supplementary Table 1).

220  
221 A significant decrease in IgG titers was found in 92.6% of patients (50/54) between both  
222 timepoints (Fig. 4B and Supplementary Table 1). Average specific IgG titers declined  
223 from 1520.84 BAU/mL in V1 to 780.88 BAU/mL in V2. This decrease was observed in  
224 the whole sample, though it was only statistically significant in the subgroup of individuals  
225 older than 40 years (Fig. 4C). Our results show an uncoupled humoral and cellular  
226 response in these patients, with antibody titers peaking already at V1, whereas T cell  
227 activation peaks at V2 (Fig.4). A dissociation between both arms of adaptive immunity  
228 has also been described in euploid individuals infected with SARS-CoV-2, and the  
229 development of an overt antibody response is not always accompanied by detectable T  
230 cell specific activation (Grifoni et al., 2020).

231  
232 Our findings show that an immune adaptive response is achieved in DS individuals three  
233 months after SARS-CoV-2 vaccination lasting, at least, up to six months after  
234 vaccination. The degree of protection conveyed by these vaccination-elicited  
235 immunological changes should nonetheless be carefully interpreted. Recent reports still  
236 show an increased hazard ratio for COVID-19 hospital admission (2.55-fold increase)  
237 and mortality rate (12.7 fold increase) in DS patients, despite vaccination with one or two  
238 doses of either ChAdOx1 nCoV-19 or BNT162b2 (Hippisley-Cox et al., 2021). It is likely  
239 that other mechanisms beyond viral infection, and probably related to the intrinsic  
240 proinflammatory status present in patients with DS, operate to lead to a worse outcome  
241 even in vaccinated individuals. These indirect findings support the generalization of  
242 current recommendations to promote booster doses in the DS population. Moreover,  
243 because we observed a more robust response to vaccination in individuals with DS  
244 younger than 40 years, we believe our results lend further support to the  
245 recommendation of prioritizing the administration of an additional vaccine booster dose  
246 preferably in adults with DS over 40 years.

247  
248 Yet unexplored but interesting issues are whether and how long vaccine-elicited  
249 responses persist over time in these patients. We are currently collecting samples to  
250 assess the evolution of humoral and cellular immunity up to twelve months after  
251 vaccination. Meanwhile, DS individuals over 40 years are already being administered a  
252 third dose of mRNA SARS-CoV-2 vaccine in Spain at the time of this publication.  
253 Analyzing the impact of this additional booster dose in their immune response will also  
254 be of great interest.

## 255 256 **MATERIALS AND METHODS**

### 257 258 **Study population**

259  
260 This descriptive study was conducted with serological samples obtained from SD donors  
261 at La Princesa University Hospital, a tertiary level hospital in Madrid. Research subjects  
262 were consecutively recruited from those attending the Adult Down Syndrome outpatient  
263 unit, who consented to vaccination against SARS-CoV-2 during the 2021 COVID-19

264 vaccination season. The recruitment period ran from February 2021 to June 2021, and  
265 subject follow-up is ongoing at the time of this interim analysis.

266 Adults with DS over 18 years were considered eligible for participation in the study. DS  
267 diagnosis was established with a karyotype or compatible typical phenotype. Because  
268 the selection of a specific vaccine type (mRNA, adenoviral, etc) or regime depended on  
269 local availability and on the directives issued by the Spanish Ministry of Health -which  
270 have varied over time and between regions-, we determined that subject selection should  
271 not be limited to any single vaccine type. Inclusion in this study did not influence  
272 vaccination eligibility or regime, nor did it play a part in the usual clinical care received  
273 by adults with DS.

274 Patients were not eligible to participate in the study if they had a history of prior  
275 anaphylactic reaction to other vaccines/vaccine components or had were limited in their  
276 mobility and had strong difficulties to complete follow-up (i.e., many individuals living in  
277 residential settings).

### 278 **Detection of specific anti-SARS-CoV-2 IgG**

279  
280 All the samples were frozen at -20°C after extraction. This is a standard of care that  
281 allows future serological assessments in case of need. Antibody titers were obtained by  
282 *SARS CoV-2 IgG II QUANT Alinity (Abbott®)*. This assay is an automated, two-step  
283 immunoassay for the quantitative determination of IgG antibodies to SARS-CoV-2  
284 against the spike receptor-binding domain (RBD) of SARS-CoV-2 in human serum using  
285 chemiluminescent microparticle immunoassay (CMIA).

286 SARS-CoV-2 IgG II Quant assay has demonstrated the ability to detect the spike RBD-  
287 based vaccine response in longitudinal samples from individuals both with and without  
288 prior COVID-19 infection (Ebinger et al., 2021; Narasimhan et al., 2021; Predecki et al.,  
289 2021).

290 The interpretation of the results has been done following the criteria of the manufacturer,  
291 considering a negative result when a result <7,1 BAU/ mL was obtained. A positive result  
292 has been considered when a quantifiable result of ≥7.2 BAU/mL was obtained. The  
293 system has an analytical measurement range of 2,98-5680 BAU/mL. When there is >  
294 5870 BAU/mL in the serum, the system reports it as > 5870 BAU/mL. The company  
295 reports a sensitivity of 99.3% and a specificity of 99.5% for this assay. We have  
296 expressed our results in BAU/mL (Binding antibody unit/mL). In line with the WHO  
297 International Standard study, the mathematical relationship of Abbott AU/mL unit to WHO  
298 BAU/mL unit would follow the equation:  $BAU/mL = 0.142 \times AU/mL$   
299 (STANDARDIZATION).

300

### 301 **PBMC Isolation and Culture**

302 Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque (Pan-  
303 Biotech), following manufacturer's instructions, and cryopreserved in liquid N2 in fetal  
304 bovine serum (HyClone TM) containing 10% DMSO (Inilab) and 1%  
305 penicillin/streptomycin (GIBCO) until use. For flow cytometry assays,  $2 \times 10^5$  cells per well  
306 were cultured for 24h at 37°C and 5%CO2 atmosphere, in the presence of different  
307 SARS-COV-2 peptide pools (PepMixTM; JPT Peptide Technologies). Pools included  
308 peptides from S1, S2 and RBD from spike (S) protein, VME1 (membrane protein), NCAP  
309 (nucleoprotein) and Mpro (Cys-like protease, nsp5) (1µg/ml) in V0, and S1, S2 and RBD  
310 for V1/V2. A positive control with staphylococcal enterotoxin B (SEB; Sigma Aldrich)  
311 (1µg/ml), and a negative control with human β-actin peptide pool (PepMixTM; JPT  
312 Peptide Technologies) (1µg/ml) were included.

### 313 **Flow Cytometry**

314 After stimulation, cells were incubated with anti-human CD3-PECy7/CD4-Pacific  
315 Orange/CD69-FITC/CXCR5-BV605/PD-1-BV786/CCR6-PerCP (BD Becton

316 Dickinson)/CD137-BV711/OX40-PE/CXCR3-APCH7 (Biolegend) for 30 min.  
317 Subsequently, cells were washed and finally resuspended in 200µl PBS 1x. All the  
318 samples were acquired on a BD FACSCanto II flow cytometer (BD Becton Dickinson).  
319 The gating strategy for stimulated T cells is provided in Suppl Fig. 1: CD4+ T cells were  
320 identified as positive for CD3 and CD4 markers. Activated CD4+ cells were defined as  
321 double positive for OX40 and CD137. SARS-CoV-2-responsive Th1 and Th2 were  
322 defined as OX40+CD137+ cells within CXCR3+CCR6- and CXCR3-CCR6- subsets  
323 respectively. SARS-CoV-2-specific cTfh cells were defined as OX40+CD137+ double  
324 positive cells within CD4+CXCR5+ and CD4+CXCR5+PD-1hi populations. CD8+ T cells  
325 were identified as positive for CD3 and negative for CD4 staining, and activated CD8+  
326 defined as CD69 and CD137 double positive cells. Flow cytometry data were analyzed  
327 using FlowJo software (BD Becton Dickinson).

328 Specific T cell response was determined by subtracting the percentage of either CD4+  
329 OX40+CD137+ or CD8+ CD69+CD137+ in the presence of β-actin peptides from that  
330 obtained with SEB or SARS-CoV-2 peptides (specific percentage). A positive result was  
331 considered for samples with specific percentage equal or above the median two-fold  
332 standard deviation of all negative controls (0.82% for OX40/CD137 and 0.93% for  
333 CD69/CD137).

### 334 **Ethical considerations**

335 This project was approved by the institutional IRB at La Princesa University Hospital  
336 (register number: 4386), meets international standards of data protection and is in line  
337 with general good practice guidelines and those established in the Declaration of  
338 Helsinki.

### 339 **Statistical analysis**

340 Categorical data were described as frequencies (percentages) and quantitative  
341 variables, as mean (SD) or median (IQR). Quantitative variables were represented in bar  
342 graphs as mean ± standard deviation (SD), or in box-and-whiskers plots. For comparison  
343 between populations, analysis of variance was performed. To analyze statistically  
344 significant differences in variables following a non-normal distribution, Kruskal-Wallis test  
345 for unpaired samples and Friedman test for paired samples were used. The statistical  
346 significance threshold was set at  $p < 0.05$ . All data analyses were performed using Graph  
347 Pad Prism 8 Software (GraphPad Software, USA, [www.graphpad.com](http://www.graphpad.com)), R (version  
348 4.0.0), and SPSS.

### 349 **Online supplemental material**

350 Supplemental material includes Supplemental Table 1 (detailed specific IgG titers in  
351 vaccinated DS patients), Supplemental Figure 1 (gating strategy for flow cytometry  
352 assays) and Supplemental Figure 2 (gender and age distribution of T helper subsets in  
353 vaccinated DS patients).  
354  
355

### 356 **ACKNOWLEDGEMENTS**

357 This work was supported by grants to A.A.: FIS PI19/01491 (Fondo de Investigación  
358 Sanitaria del Instituto de Salud Carlos III with co-funding from the Fondo Europeo de  
359 Desarrollo Regional FEDER) and Sociedad Cooperativa de Viviendas Buen Suceso,  
360 S.Coop.Mad. To A.A. and F.S-M.: CIBER Cardiovascular from the Instituto de Salud  
361 Carlos III (Fondo de Investigación Sanitaria del Instituto de Salud Carlos III with co-  
362 funding from the Fondo Europeo de Desarrollo Regional; FEDER). To F.S-M.: “Fondos  
363 Supera COVID19” (Banco de Santander and CRUE), “Ayuda Covid 2019” and  
364 “Inmunovacter” REACT-UE (Comunidad de Madrid). DRA was supported by the Fondo  
365 de Investigaciones Sanitarias (FIS grant PI19/00634, from the Ministerio de Economía y  
366 Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional  
367 Development Fund (ERDF) "A way to make Europe" and the Fondation Jérôme Lejeune



368 (grant no. 2021a-2069). FM is supported by the Jérôme Lejeune Foundation (grant no.  
369 2017b-1711). The Adult Down Syndrome Outpatient unit at Hospital Universitario de La  
370 Princesa is grateful to Licenciado don Jesús Coronado Hinojosa for his financial support  
371 of the research endeavors of our unit.

## 372 **COMPETING INTERESTS**

373 The authors declare no competing financial interests.

## 374 **AUTHOR CONTRIBUTIONS**

- 375 • Project coordination, original idea: AA, AG, DRA
- 376 • Subject recruitment and follow-up: FM, DRA
- 377 • Variable collection and database compilation: GM, AY, LE
- 378 • Initial sample processing, and sample collection preservation/storage: GM, AY, LE, NR
- 379 • Serological assays: AG, AY
- 380 • Cellular immunity activation assays: AA, LE, NR
- 381 • Lab coordination: AA, AG
- 382 • Statistical analysis and data mining: AG, AA, DRA
- 383 • Results evaluation, manuscript drafting and publication: All

384

## 385 **REFERENCES**

- 386 Brodin, P. 2021. Immune determinants of COVID-19 disease presentation and severity. *Nat Med*  
387 27:28-33.
- 388 Carsetti, R., D. Valentini, V. Marcellini, M. Scarsella, E. Marasco, F. Giustini, A. Bartuli, A. Villani,  
389 and A.G. Ugazio. 2015. Reduced numbers of switched memory B cells with high terminal  
390 differentiation potential in Down syndrome. *Eur J Immunol* 45:903-914.
- 391 Chung, H., P.H.R. Green, T.C. Wang, and X.F. Kong. 2021. Interferon-Driven Immune  
392 Dysregulation in Down Syndrome: A Review of the Evidence. *J Inflamm Res* 14:5187-  
393 5200.
- 394 Clift, A.K., C.A.C. Coupland, R.H. Keogh, H. Hemingway, and J. Hippisley-Cox. 2021. COVID-19  
395 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults. *Ann*  
396 *Intern Med* 174:572-576.
- 397 Costa-Carvalho, B.T., R.M. Martinez, A.T. Dias, C.A. Kubo, P. Barros-Nunes, L. Leiva, D. Solé, M.M.  
398 Carneiro-Sampaio, C.K. Naspitz, and R.U. Sorensen. 2006. Antibody response to  
399 pneumococcal capsular polysaccharide vaccine in Down syndrome patients. *Braz J Med*  
400 *Biol Res* 39:1587-1592.
- 401 Dan, J.M., J. Mateus, Y. Kato, K.M. Hastie, E.D. Yu, C.E. Faliti, A. Grifoni, S.I. Ramirez, S. Haupt, A.  
402 Frazier, C. Nakao, V. Rayaprolu, S.A. Rawlings, B. Peters, F. Krammer, V. Simon, E.O.  
403 Saphire, D.M. Smith, D. Weiskopf, A. Sette, and S. Crotty. 2021. Immunological memory  
404 to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 371:
- 405 De Toma, I., and M. Dierssen. 2021. Network analysis of Down syndrome and SARS-CoV-2  
406 identifies risk and protective factors for COVID-19. *Sci Rep* 11:1930.
- 407 Ebinger, J.E., J. Fert-Bober, I. Printsev, M. Wu, N. Sun, J.C. Prostko, E.C. Frias, J.L. Stewart, J.E.  
408 Van Eyk, J.G. Braun, S. Cheng, and K. Sobhani. 2021. Antibody responses to the  
409 BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med*
- 410 Eijssvoegel, N.B., M.I. Hollegien, V.L.A. Bok, A.G. Derksen Lubsen, F.P.J. Dikken, S.A.C.A. Leenders,  
411 A. Pijning, E. Post, M. Wojciechowski, M. Hilbink, and E. de Vries. 2017. Declining  
412 antibody levels after hepatitis B vaccination in Down syndrome: A need for booster  
413 vaccination? *J Med Virol* 89:1682-1685.
- 414 Esparcia-Pinedo L, Martínez-Fleta P, Ropero N, Vera-Tomé P, Reyburn .H. T, Casanovas J. M.,  
415 Rodríguez-Frade JM, Vales-Gomez. M, Vilches C, Martín-Gayo E, Muñoz-Calleja C,

- 416 Sanchez-Madrid F, and Alfranca A. 2022. CD4+ T cell Immune specificity changes after  
417 vaccination in healthy and COVID-19 convalescent subjects. In *Frontiers in Immunology*.
- 418 Espinosa, J.M. 2020. Down Syndrome and COVID-19: A Perfect Storm? *Cell Rep Med* 1:100019.
- 419 Franciotta, D., A. Verri, E. Zardini, L. Andreoni, M. De Amici, R. Moratti, and L. Nespoli. 2006.  
420 Interferon-gamma- and interleukin-4-producing T cells in Down's syndrome. *Neurosci*  
421 *Lett* 395:67-70.
- 422 Grifoni, A., D. Weiskopf, S.I. Ramirez, J. Mateus, J.M. Dan, C.R. Moderbacher, S.A. Rawlings, A.  
423 Sutherland, L. Premkumar, R.S. Jadi, D. Marrama, A.M. de Silva, A. Frazier, A.F. Carlin,  
424 J.A. Greenbaum, B. Peters, F. Krammer, D.M. Smith, S. Crotty, and A. Sette. 2020. Targets  
425 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and  
426 Unexposed Individuals. *Cell* 181:1489-1501.e1415.
- 427 Hippisley-Cox, J., C.A. Coupland, N. Mehta, R.H. Keogh, K. Diaz-Ordaz, K. Khunti, R.A. Lyons, F.  
428 Kee, A. Sheikh, S. Rahman, J. Valabhji, E.M. Harrison, P. Sellen, N. Haq, M.G. Semple,  
429 P.W.M. Johnson, A. Hayward, and J.S. Nguyen-Van-Tam. 2021. Risk prediction of covid-  
430 19 related death and hospital admission in adults after covid-19 vaccination: national  
431 prospective cohort study. *BMJ* 374:n2244.
- 432 Huggard, D., D.G. Doherty, and E.J. Molloy. 2020. Immune Dysregulation in Children With Down  
433 Syndrome. *Front Pediatr* 8:73.
- 434 Hüls, A., A.C.S. Costa, M. Dierssen, R.A. Baksh, S. Bargagna, N.T. Baumer, A.C. Brandão, A. Carfi,  
435 M. Carmona-Iragui, B.A. Chicoine, S. Ghosh, M. Lakhanpaul, C. Manso, M.A. Mayer, M.  
436 Del Carmen Ortega, D.R. de Asua, A.S. Rebillat, L.A. Russell, G. Sgandurra, D. Valentini,  
437 S.L. Sherman, and A. Strydom. 2020. An international survey on the impact of COVID-19  
438 in individuals with Down syndrome. *medRxiv*
- 439 Hüls, A., A.C.S. Costa, M. Dierssen, R.A. Baksh, S. Bargagna, N.T. Baumer, A.C. Brandão, A. Carfi,  
440 M. Carmona-Iragui, B.A. Chicoine, S. Ghosh, M. Lakhanpaul, C. Manso, M.A. Mayer,  
441 M.D.C. Ortega, D.R. de Asua, A.S. Rebillat, L.A. Russell, G. Sgandurra, D. Valentini, S.L.  
442 Sherman, A. Strydom, and T.R.C.-. Initiative. 2021. Medical vulnerability of individuals  
443 with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society  
444 and the UK ISARIC4C survey. *EClinicalMedicine* 33:100769.
- 445 Joshi, A.Y., R.S. Abraham, M.R. Snyder, and T.G. Boyce. 2011. Immune evaluation and vaccine  
446 responses in Down syndrome: evidence of immunodeficiency? *Vaccine* 29:5040-5046.
- 447 Kong, X.F., L. Worley, D. Rinchai, V. Bondet, P.V. Jithesh, M. Goulet, E. Nonnotte, A.S. Rebillat,  
448 M. Conte, C. Mircher, N. Gürtler, L. Liu, M. Migaud, M. Elanbari, T. Habib, C.S. Ma, J.  
449 Bustamante, L. Abel, A. Ravel, S. Lyonnet, A. Munnich, D. Duffy, D. Chaussabel, J.L.  
450 Casanova, S.G. Tangye, S. Boisson-Dupuis, and A. Puel. 2020. Three Copies of Four  
451 Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome.  
452 *J Clin Immunol* 40:807-819.
- 453 Malle, L., and D. Bogunovic. 2021. Down syndrome and type I interferon: not so simple. *Curr*  
454 *Opin Immunol* 72:196-205.
- 455 Mateus, J., A. Grifoni, A. Tarke, J. Sidney, S.I. Ramirez, J.M. Dan, Z.C. Burger, S.A. Rawlings, D.M.  
456 Smith, E. Phillips, S. Mallal, M. Lammers, P. Rubiro, L. Quiambao, A. Sutherland, E.D. Yu,  
457 R. da Silva Antunes, J. Greenbaum, A. Frazier, A.J. Markmann, L. Premkumar, A. de Silva,  
458 B. Peters, S. Crotty, A. Sette, and D. Weiskopf. 2020. Selective and cross-reactive SARS-  
459 CoV-2 T cell epitopes in unexposed humans. *Science* 370:89-94.
- 460 Narasimhan, M., L. Mahimainathan, E. Araj, A.E. Clark, J. Markantonis, A. Green, J. Xu, J.A.  
461 SoRelle, C. Alexis, K. Fankhauser, H. Parikh, K. Wilkinson, A. Reczek, N. Kopplin, S.  
462 Yekkaluri, J. Balani, A. Thomas, A.G. Singal, R. Sarode, and A. Muthukumar. 2021. Clinical  
463 evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM  
464 assays among infected, recovered, and vaccinated groups. *J Clin Microbiol*
- 465 Ottaviano, G., J. Gerosa, M. Santini, P. De Leo, A. Vecchione, T. Jofra, C. Trimarchi, M. De  
466 Pellegrin, M. Agosti, A. Aiuti, M. Marinoni, M.P. Cicalese, and G. Fousteri. 2020. A

- 467 prevalent CXCR3(+) phenotype of circulating follicular helper T cells indicates humoral  
468 dysregulation in children with Down syndrome. *J Clin Immunol* 40:447-455.
- 469 Pairo-Castineira, E., S. Clohisey, L. Klaric, A.D. Bretherick, K. Rawlik, D. Pasko, S. Walker, N.  
470 Parkinson, M.H. Fourman, C.D. Russell, J. Furniss, A. Richmond, E. Gountouna, N.  
471 Wrobel, D. Harrison, B. Wang, Y. Wu, A. Meynert, F. Griffiths, W. Oosthuyzen, A.  
472 Kousathanas, L. Moutsianas, Z. Yang, R. Zhai, C. Zheng, G. Grimes, R. Beale, J. Millar, B.  
473 Shih, S. Keating, M. Zechner, C. Haley, D.J. Porteous, C. Hayward, J. Yang, J. Knight, C.  
474 Summers, M. Shankar-Hari, P. Klenerman, L. Turtle, A. Ho, S.C. Moore, C. Hinds, P.  
475 Horby, A. Nichol, D. Maslove, L. Ling, D. McAuley, H. Montgomery, T. Walsh, A.C. Pereira,  
476 A. Renieri, X. Shen, C.P. Ponting, A. Fawkes, A. Tenesa, M. Caulfield, R. Scott, K. Rowan,  
477 L. Murphy, P.J.M. Openshaw, M.G. Semple, A. Law, V. Vitart, J.F. Wilson, J.K. Baillie, G.  
478 Investigators, I.C. Investigators, C.-H.G. Initiative, a. Investigators, B. Investigators, and  
479 G.-C. Investigators. 2021. Genetic mechanisms of critical illness in COVID-19. *Nature*  
480 591:92-98.
- 481 Perera, B., R. Laugharne, W. Henley, A. Zabel, K. Lamb, D. Branford, K. Courtanay, R. Alexander,  
482 K. Purandare, A. Wijeratne, V. Radhakrishnan, E. McNamara, Y. Daareewoo, I.  
483 Sawhney, M. Scheepers, G. Taylor, and R. Shankar. 2020. COVID-19 deaths in people  
484 with intellectual disability in the UK and Ireland: descriptive study. *BJPsych Open* 6:e123.
- 485 Predecki, M., C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A.D. Pria, L.  
486 Lightstone, X.N. Xu, W. Barclay, S.P. McAdoo, P. Kelleher, and M. Willicombe. 2021.  
487 Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose  
488 BNT162b2 vaccine. *Lancet* 397:1178-1181.
- 489 Real de Asua, D., M.A. Mayer, M.D.C. Ortega, J.M. Borrel, T.J. Bermejo, D. González-Lamuño, C.  
490 Manso, F. Moldenhauer, M. Carmona-Iragui, A. Hüls, S.L. Sherman, A. Strydom, R. de la  
491 Torre, and M. Dierssen. 2021. Comparison of COVID-19 and Non-COVID-19 Pneumonia  
492 in Down Syndrome. *J Clin Med* 10:
- 493 Ruan, Q., K. Yang, W. Wang, L. Jiang, and J. Song. 2020. Clinical predictors of mortality due to  
494 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. In *Intensive*  
495 *Care Med*. 846-848.
- 496 Sadarangani, M., A. Marchant, and T.R. Kollmann. 2021. Immunological mechanisms of vaccine-  
497 induced protection against COVID-19 in humans. *Nat Rev Immunol* 21:475-484.
- 498 Schoch, J., T.R. Rohrer, M. Kaestner, H. Abdul-Khaliq, L. Gortner, U. Sester, M. Sester, and T.  
499 Schmidt. 2017. Quantitative, Phenotypical, and Functional Characterization of Cellular  
500 Immunity in Children and Adolescents With Down Syndrome. *J Infect Dis* 215:1619-  
501 1628.
- 502 Sekine, T., A. Perez-Potti, O. Rivera-Ballesteros, K. Strålin, J.B. Gorin, A. Olsson, S. Llewellyn-  
503 Lacey, H. Kamal, G. Bogdanovic, S. Muschiol, D.J. Wullimann, T. Kammann, J. Emgård, T.  
504 Parrot, E. Folkesson, O. Rooyackers, L.I. Eriksson, J.I. Henter, A. Sönnernborg, T. Allander,  
505 J. Albert, M. Nielsen, J. Klingström, S. Gredmark-Russ, N.K. Björkström, J.K. Sandberg,  
506 D.A. Price, H.G. Ljunggren, S. Aleman, M. Buggert, and K.C.-S. Group. 2020. Robust T Cell  
507 Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*  
508 183:158-168.e114.
- 509 STANDARDIZATION, E.C.O.B. Establishment of the WHO International Standard and Reference  
510 Panel for anti-SARS-CoV-2 antibody. In WHO/BS/2020.2403.
- 511 Tyllis, T.S., K.A. Fenix, T.S. Norton, E.E. Kara, D.R. McKenzie, S.C. David, M. Alsharifi, D. Yu, S.R.  
512 McColl, and I. Comerford. 2021. CXCR5. *Front Immunol* 12:626199.
- 513 Valentine, K.M., and K.K. Hoyer. 2019. CXCR5+ CD8 T Cells: Protective or Pathogenic? *Front*  
514 *Immunol* 10:1322.
- 515 Valentini, D., V. Marcellini, S. Bianchi, A. Villani, M. Facchini, I. Donatelli, M.R. Castrucci, E.  
516 Marasco, C. Farroni, and R. Carsetti. 2015. Generation of switched memory B cells in

517 response to vaccination in Down syndrome children and their siblings. *Vaccine* 33:6689-  
518 6696.  
519 Wadman, M. 2020. People with Down syndrome face high risk from coronavirus. *Science*  
520 370:1384-1385.  
521 Woldemeskel, B.A., A.K. Kwaa, C.C. Garliss, O. Laeyendecker, S.C. Ray, and J.N. Blankson. 2020.  
522 Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. *J Clin*  
523 *Invest* 130:6631-6638.  
524

525

526 **FIGURE LEGENDS**

527 **Figure 1. T cell response in Down Syndrome patients after SARS-CoV-2**  
528 **vaccination.** SARS-CoV-2-specific CD4+ (A.) and CD8+ (B.) lymphocytes in DS  
529 patients in Visit 0, Visit 1 and Visit 2. *Upper panels*, pie charts indicate the percentage of  
530 patients with (black) or without (white) T cell immunity against SARS-CoV-2 in each visit.  
531 *Lower panels*, number of patients with T cell response against specific peptide pools in  
532 each visit.

533 **Figure 2. T helper subsets in Down Syndrome patients after SARS-CoV-2**  
534 **vaccination.** A., *Left*, percentage of SARS-CoV-2-specific Th1 and Th2 CD4+  
535 lymphocytes in visits 1 (V1) and 2 (V2); *right*, percentage of SEB-activated Th1 and Th2  
536 CD4+ cells in visits 1 and 2. B., Graphics show the percentage of S1-specific (*left*) and  
537 S2-specific (*right*) Th1 and Th2 CD4+ subsets in visits 1 and 2. Mean+SD is shown.  
538 \*p<0.05; \*\*p<0.01; ns, non-significant.

539 **Figure 3. Circulating Tfh in Down Syndrome patients after SARS-CoV-2**  
540 **vaccination.** A., Graphics show the percentage of circulating CD4+CXCR5+ (*left*) and  
541 CD4+CXCR5+PD-1hi (*right*) cells in visits 1 and 2. Mean+SD is shown. B., Graphics  
542 show the percentage of SARS-CoV-2-specific CD8+CXCR5+ (*left*) and PD-1hi  
543 expression within CD8+CXCR5+ population (*right*) in visits 1 and 2 (n=11). \*p<0.05;  
544 \*\*p<0.01; ns, non-significant.

545 **Figure 4. Humoral response in Down Syndrome patients after SARS-CoV-2**  
546 **vaccination.** A., Percentage of DS donors with detectable anti-SARS-CoV-2 S IgG in  
547 visits 0, 1 and 2. B., Specific anti-SARS-CoV-2 S IgG titers in DS patients in visits 0 (V0),  
548 1 (V1), and 2 (V2). C., Specific anti-SARS-CoV-2 S IgG titers in visits 0 (V0), 1 (V1), and  
549 2 (V2) in DS patients  $\leq$  40 years (*left*) or  $>$  40 years (*right*). \*\*\*\*p<0.0001; \*\*\*p<0.001; ns,  
550 non-significant.

551

552

553 **TABLE 1. Demographic and clinical characteristics of the study sample**

554

	n = 55
Age (years)	44 ± 10
Sex (male)	25 (44%)
Living situation	
Family home	31 (55%)
Supervised group home	1 (2%)
Institutionalized	11 (20%)
Degree of intellectual disability	
Mild	45 (80%)
Moderate	9 (16%)
Severe	2 (4%)
Comorbidities <sup>(&amp;)</sup>	
Skin conditions	36 (64%)
Hypothyroidism	29 (51%)
Gastrointestinal disorders	21 (37,5%)
Obstructive sleep apnea	19 (34%)
Congenital heart disease	10 (18%)
Alzheimer's disease	11 (20%)
Epilepsy	2 (4%)
Vaccine type	
BNT162b2 (Comirnaty®, Pfizer/BioNTech)	48 (86%)
mRNA-1273 (Spikevax®, Moderna)	7 (12,5%)
ChAdOx1 (Vaxzevria®, Oxford/Astra Zeneca)	1 (1,5%)
Adverse reactions <sup>(#)</sup>	
To first vaccine dose	6 (11%)
To second vaccine dose	6 (11%)
History of COVID-19 before vaccination	14 (25%)
Vaccinated in the past 12 months <sup>(*)</sup>	10 (18%)

555 (&): Only comorbidities that have been linked to a worse prognosis of SARS-CoV-2  
556 infection or to immune dysregulation are presented.


557 (#): Noted adverse reactions were all mild (involving either local pain, fever or malaise,  
558 lasting less than 24 h).

559 (\*): Other than vaccination against SARS-CoV-2 (i.e., influenza or pneumococcal  
560 vaccination)


561

## FIGURES

Figure 1



**Figure 2**





**Figure 3**




Figure 4

